Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 317

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 317
---
30, 2024 for the Successor and December 31,
2023 for the Predecessor, the fair value of derivative liabilities were classified as follows:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at January 1, 2024                       |     | $       | - |     | $       | - |     | $       |    320,117 |   |     | $     |    320,117 |   |
| Reclassification of warrant liability to equity  |     |         | - |     |         | - |     |         |   (320,117 | ) |     |       |   (320,117 | ) |
| Balance at February 13, 2024                     |     |         | - |     |         | - |     |         |          - |   |     |       |          - |   |
| Earnout liability (Successor):                   |     |         |   |     |         |   |     |         |            |   |     |       |            |   |
| Balance at February 14, 2024                     |     |         | - |     |         | - |     |         |  4,900,000 |   |     |       |  4,900,000 |   |
| (Gain) on revaluation of earnout liability       |     |         | - |     |         | - |     |         | (1,800,000 | ) |     |       | (1,800,000 | ) |
| Balance at March 31, 2024                        |     |         | - |     |         | - |     |         |  3,100,000 |   |     |       |  3,100,000 |   |
| (Gain) on revaluation of earnout liability       |     |         | - |     |         | - |     |         | (2,900,000 | ) |     |       | (2,900,000 | ) |
| Balance